• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Water Tower Research Issues Statement Regarding Technical Interruption During Anixa Biosciences Fireside Chat

    11/12/25 11:00:00 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANIX alert in real time by email

    St. Petersburg, FL, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Water Tower Research (WTR) issued the following statement regarding a technical issue that occurred during its recent Fireside Chat with Anixa Biosciences, Inc. (NASDAQ:ANIX), held on Tuesday, November 11, 2025.

    Due to an issue with the firm's streaming service, the live broadcast of the event was interrupted.

    The session was fully recorded and is now available for on-demand viewing at the link below:

    Access the Replay: https://us06web.zoom.us/webinar/register/WN_LiTi8dfgRXuVPaFYq5E7OQ

    "We sincerely apologize for the inconvenience caused by this unforeseen technical disruption," said Shawn Severson, Co-Founder and CEO of Water Tower Research. "Our goal is always to deliver a seamless experience for our clients and the investment community. We have since identified and resolved the technical issue to ensure future sessions proceed without interruption. We appreciate everyone's understanding and continued engagement with Water Tower Research's open-access Fireside Chat Series."

    The Water Tower Research Fireside Chat Series is designed to connect investors with management teams from innovative public and private companies through open-access, interactive discussions.

    For additional information or upcoming events, please visit www.watertowerresearch.com. If there are any questions, please email [email protected].

    About Water Tower Research

    Water Tower Research is modernizing investor engagement through research-driven communications. Sound investment research begins with good information. At WTR, we help companies and investors connect by creating expert information flow and strategies that are the foundation of a successful modern investor relations platform. Our analysts and capital markets professionals bring decades of unrivaled Wall Street experience and insight into a new digital world of investor communications and engagement. Our research and investor content is distributed across traditional research aggregators Bloomberg, FactSet, etc., proprietary direct distribution lists, social media, search engines, and our website. As a result, every institutional and retail investor has equal access to our high-quality company research. Our mission is to help companies take control of their IR program and proactively reach investors while bringing investors a consistent flow of quality information to help them understand our clients' businesses, industries, and the investment opportunities they present.



    Name: Water Tower Research LLC
    Email: [email protected]
    Job Title: WTR Investor Engagement

    Primary Logo

    Get the next $ANIX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANIX

    DatePrice TargetRatingAnalyst
    3/21/2025$10.00Buy
    Maxim Group
    12/23/2022$8.00Buy
    Chardan Capital Markets
    More analyst ratings

    $ANIX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Anixa Biosciences with a new price target

    Maxim Group initiated coverage of Anixa Biosciences with a rating of Buy and set a new price target of $10.00

    3/21/25 8:14:33 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets initiated coverage on Anixa Biosciences with a new price target

    Chardan Capital Markets initiated coverage of Anixa Biosciences with a rating of Buy and set a new price target of $8.00

    12/23/22 7:26:43 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. initiated coverage on Anixa Biosciences with a new price target

    HC Wainwright & Co. initiated coverage of Anixa Biosciences with a rating of Buy and set a new price target of $11.00

    4/12/21 6:30:29 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANIX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Titterton Lewis H Jr bought $30,800 worth of shares (10,000 units at $3.08), increasing direct ownership by 1% to 953,334 units (SEC Form 4)

    4 - Anixa Biosciences Inc (0000715446) (Issuer)

    8/4/25 9:00:05 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Kumar Amit bought $15,800 worth of shares (5,000 units at $3.16), increasing direct ownership by 0.87% to 579,925 units (SEC Form 4)

    4 - Anixa Biosciences Inc (0000715446) (Issuer)

    7/31/25 9:00:04 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baskies Arnold M bought $16,950 worth of shares (5,000 units at $3.39), increasing direct ownership by 4% to 125,000 units (SEC Form 4)

    4 - Anixa Biosciences Inc (0000715446) (Issuer)

    7/21/25 8:30:06 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANIX
    Leadership Updates

    Live Leadership Updates

    View All

    Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development

    SAN JOSE, Calif., Oct. 7, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Suyasha Gupta as Senior Director of Clinical Development. In this role, Ms. Gupta will work closely with Dr. Pamela Garzone, Chief Development Officer, to oversee the Company's ongoing Phase 1 breast cancer vaccine and Phase 1 ovarian cancer CAR-T therapy clinical trials, as well as the upcoming Phase 2 breast cancer vaccine clinical trial. Suyasha Gupta is

    10/7/24 8:30:00 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja

    Dr. Amit Kumar interviewed in latest episode, 'The Vaccine That Could End Breast Cancer' SAN JOSE, Calif., May 6, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced a podcast interview of Anixa Chairman and CEO Dr. Amit Kumar by oncologist Dr. Sanjay Juneja, with more than 500,000 followers through his media brand 'TheOncDoc.' The interview is broadly available on podcast platforms and can be viewed now on YouTube. In the "Target: Cancer

    5/6/24 8:05:00 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board

    SAN JOSE, Calif., April 18, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced the appointment of Sanjay Juneja, MD to its Cancer Business Advisory Board. Anixa Chairman and CEO Dr. Amit Kumar stated, "Dr. Juneja is an accomplished medical oncologist who has earned status as a top media personality on cancer prevention and treatment innovations. His influence has earned him invitations to help shape healthcare policy, and, most important

    4/18/24 8:20:00 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANIX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Kumar Amit exercised 200,000 shares at a strike of $2.92 and covered exercise/tax liability with 169,439 shares, increasing direct ownership by 5% to 610,486 units (SEC Form 4)

    4 - Anixa Biosciences Inc (0000715446) (Issuer)

    10/31/25 9:13:33 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Titterton Lewis H Jr bought $30,800 worth of shares (10,000 units at $3.08), increasing direct ownership by 1% to 953,334 units (SEC Form 4)

    4 - Anixa Biosciences Inc (0000715446) (Issuer)

    8/4/25 9:00:05 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Kumar Amit bought $15,800 worth of shares (5,000 units at $3.16), increasing direct ownership by 0.87% to 579,925 units (SEC Form 4)

    4 - Anixa Biosciences Inc (0000715446) (Issuer)

    7/31/25 9:00:04 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANIX
    SEC Filings

    View All

    SEC Form EFFECT filed by Anixa Biosciences Inc.

    EFFECT - Anixa Biosciences Inc (0000715446) (Filer)

    10/1/25 12:15:26 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-3 filed by Anixa Biosciences Inc.

    S-3 - Anixa Biosciences Inc (0000715446) (Filer)

    9/10/25 5:25:28 PM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Anixa Biosciences Inc.

    10-Q - Anixa Biosciences Inc (0000715446) (Filer)

    9/10/25 4:30:46 PM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANIX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Anixa Biosciences Inc.

    SC 13D - Anixa Biosciences Inc (0000715446) (Subject)

    5/3/24 1:31:16 PM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Anixa Biosciences Inc. (Amendment)

    SC 13D/A - Anixa Biosciences Inc (0000715446) (Subject)

    1/16/24 5:29:43 PM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Anixa Biosciences, Inc. (Amendment)

    SC 13D/A - Anixa Biosciences Inc (0000715446) (Subject)

    9/3/21 4:15:28 PM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANIX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Water Tower Research Issues Statement Regarding Technical Interruption During Anixa Biosciences Fireside Chat

    St. Petersburg, FL, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Water Tower Research (WTR) issued the following statement regarding a technical issue that occurred during its recent Fireside Chat with Anixa Biosciences, Inc. (NASDAQ:ANIX), held on Tuesday, November 11, 2025. Due to an issue with the firm's streaming service, the live broadcast of the event was interrupted. The session was fully recorded and is now available for on-demand viewing at the link below: Access the Replay: https://us06web.zoom.us/webinar/register/WN_LiTi8dfgRXuVPaFYq5E7OQ "We sincerely apologize for the inconvenience caused by this unforeseen technical disruption," said Shawn Severson, Co-Founder and CEO of Water Tower

    11/12/25 11:00:00 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s

    Patent Extends Protection for Novel Vaccine Targeting a Cancer Projected to Strike Nearly 300,000 U.S. Women in 2026 SAN JOSE, Calif., Nov. 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the United States Patent and Trademark Office (USPTO) will issue U.S. Patent Number 12,472,205 on November 18, 2025, covering key aspects of the Company's breast cancer vaccine technology. The patent protects novel methods of inducing an immune response to α-lactalbumin protein—a protein typically found only in normal breast tissue during lactation but also expressed in

    11/12/25 9:00:00 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025

    SAN JOSE, Calif., Nov. 10, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its Chairman and CEO, Dr. Amit Kumar, will participate in the upcoming Water Tower Research Fireside Chat Series taking place on Tuesday, November 11, 2025, at 11:00am PT. The Fireside Chat wil be hosted by Robert Sassoon, Managing Director – Healthcare at Water Tower Research, and will cover several topics, including: Overview of the Company and its clinical programsBre

    11/10/25 10:30:00 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANIX
    Financials

    Live finance-specific insights

    View All

    Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine

    – Antigen-specific T cell responses were observed at all dose levels – – IFNγ and IL-17, immune-mediated biomarkers of T cell activation, increased over time from baseline – – Vaccine was safe and well tolerated – – Conference call to commence today at 6:30 p.m. ET – SAN JOSE, Calif., Dec. 6, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced new and updated positive results from the Phase 1 clinical trial of its breast cancer vaccine. The trial is being conducted in collaboration with Cleveland Clinic with funding by a grant from the U.S. Department of Defense.

    12/6/23 6:00:00 PM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine

    – Data to be released at approximately 6:00 p.m. ET, following presentation at 2023 SABCS – – Conference call to commence at 6:30 p.m. ET – SAN JOSE, Calif., Dec. 6, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ:ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, will publicly release new data this evening from the ongoing Phase 1 clinical trial of its breast cancer vaccine, which was presented for the first time today at the 2023 San Antonio Breast Cancer Symposium ("SABCS"). All interested parties are invited to join an upcoming conference call today at 6:30 pm ET to discuss the data.

    12/6/23 4:05:00 PM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care